BMO Capital analyst Gary Nachman maintained a Buy rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) on Thursday, setting a price target of $205, which is approximately 49.73% above the present share price of $136.91.
Nachman expects Jazz Pharmaceuticals to post earnings per share (EPS) of -$6.11 for the fourth quarter of 2021.
The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Jazz Pharmaceuticals, with an average price target of $198.71.
The analysts price targets range from a high of $220 to a low of $172.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $751.81 million and a net profit of -$69.59 million. The company's market cap is $8.4 billion.
According to TipRanks.com, BMO Capital analyst Gary Nachman is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -1.3% and a 43.54% success rate.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.